ArticleHuman psychopharmacology2019
Use of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005-2017.
Article in Human psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Self-Reported Adverse Effects Associated With New Psychoactive Substance Use in a Sample of Adults From 20 US Cities.Drug and alcohol review · 2026Article
- The Epidemiology of Recreational Use and Availability of DOC and DOI in the United States.Journal of psychoactive drugs · 2025Article
- Tusi: a new ketamine concoction complicating the drug landscape.The American journal of drug and alcohol abuse · 2023Article
- Trends in drug use among nightclub and festival attendees in New York City, 2017-2022.The International journal on drug policy · 2023Article
- A narrative synthesis of research with 5-MeO-DMT.Journal of psychopharmacology (Oxford, England) · 2022Review
- Combining Neurobehavioral Analysis andACS chemical neuroscience · 2020Article
- Underreporting of drug use on a survey of electronic dance music party attendees.Addiction research & theory · 2020Article
- A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines.Human psychopharmacology · 2020Article
- NBOMes-Highly Potent and Toxic Alternatives of LSD.Frontiers in neuroscience · 2020Review
- Differential Risk for Drug Use by Sexual Minority Status among Electronic Dance Music Party Attendees in New York City.Substance use & misuse · 2020Article
- Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.Frontiers in psychiatry · 2019Article
- Increasing Willingness to Use Synthetic Drugs if Offered among Electronic Dance Music Party Attendees, 2017-2019.Journal of psychoactive drugsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThis study aims to examine patterns and first mentions of reported use of new or uncommon drugs across 13 years, among nationally representative samples in the United States.
methodsParticipants (ages ≥12) in the National Surveys on Drug Use and Health (2005-2017, N = 730,418) were provided opportunities to type in names of new or uncommon drugs they had ever used that were not specifically queried. We examined self-reported use across survey years and determined years of first mentions.
resultsFrom 2005 to 2017, there were 2,343 type-in responses for use of 79 new or uncommon synthetic drugs, and 54 were first-ever mentions of these drugs. The majority (65.8%) of mentions were phenethylamines (e.g., 2C-x, NBOMe), which were also the plurality of new drug mentions (n = 22; 40.7%). Mentions of 2C-x drugs in particular increased from 30 mentions in 2005 to 147 mentions in 2013. We estimate an upward trend in use of new or uncommon drugs between 2005 and 2017 (p < 0.001).
conclusionAlthough type-in responses on surveys are limited and underestimate prevalence of use, such responses can help inform researchers when new compounds are used. Continued surveillance of use of new and uncommon drugs is needed to inform adequate public health response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.